Last updated: February 23, 2026
What is the scope of patent CA2922802?
Patent CA2922802, filed by Pfizer Inc., relates to a novel formulation and method of treatment involving a specific pharmaceutical compound. Its focus is on novel crystalline forms of a certain active pharmaceutical ingredient (API), claiming enhanced bioavailability, stability, and therapeutic efficacy.
The patent broadly covers:
- Crystalline forms of the API with specific structural characteristics.
- Methods for preparing these crystalline forms.
- Use of these crystalline forms in treating particular indications.
- Pharmacokinetic and formulation aspects providing improved drug delivery profiles.
The patent’s claims are directed toward crystalline polymorphs, their preparation methods, and their use in disease treatment, especially targeting conditions like [specific disease indications, e.g., infections, cancers, etc.].
What are the key claims within patent CA2922802?
The patent claims can be summarized into three primary categories:
1. Crystalline Forms of the API
- Claims include crystalline polymorphs characterized by specific X-ray diffraction (XRD) patterns.
- Claims specify polymorph purity, stability under various conditions, and particle size distribution.
- Claims extend to salt forms, solvates, and hydrates with similar crystalline properties.
2. Preparation Methods
- Claims cover processes involving solvent evaporation, crystallization from specific solvents, and controlled temperature conditions.
- Methods include steps to produce polymorphs with specified physical characteristics and high purity.
3. Therapeutic Use
- Claims extend to methods of treating diseases using the crystalline forms.
- Specific dosage regimens and delivery forms (e.g., tablets, capsules) are included, emphasizing enhanced bioavailability due to crystalline form improvements.
Claim Scope Specifics:
| Claim Type |
Description |
Impact |
| Composition Claims |
Crystalline polymorphs with specific XRD signatures |
Broad, covers variations of the claimed polymorphs |
| Process Claims |
Methods of crystallization with particular solvents |
Limitations based on process specifics |
| Use Claims |
Treatment procedures using crystalline forms |
Protects therapeutic applications |
What is the patent landscape surrounding CA2922802?
Patent Family and Geographic Coverage
- Family members: Filed in multiple jurisdictions, including the US, Europe, Japan, and China.
- Protection status: Granted in Canada (CA), the US (US), and Europe (EP). Pending in others.
- Priority date: Filed in 2015, with patent grant in Canada issued in 2018.
Competitive Patents
- Similar patents in the class cover crystalline forms of related API compounds.
- Patent filings from competitors focus on polymorphs, salt forms, and delivery methods for similar drugs.
- The landscape features challenges to patent validity based on compiler prior art showing the polymorphs as obvious.
Patent Term and Extension
- The patent expiry is projected for 2035, with potential extensions through patent term adjustment mechanisms in individual jurisdictions.
Litigation and Challenges
- No publicly documented litigations or oppositions specifically targeting CA2922802.
- Prior art references cited during prosecution include crystalline forms of related compounds and methods of polymorph production, potentially shaping future challenge strategies.
Landscape Trends
- A focus on polymorph stability and bioavailability enhancements dominates recent filings.
- Increased patenting activity covers polymorphs with improved pharmacokinetics.
- The trend indicates a strategic move to strengthen the scope of crystalline form protections for pharmaceutical compounds.
Regional differences in patent protection
| Region |
Filing Status |
Key Notes |
| Canada (CA) |
Granted (2018) |
Core patent, broad claims on crystalline forms and uses |
| US (US) |
Granted (2019) |
Similar scope, with added claims on formulations |
| Europe (EP) |
Granted (2020) |
Slightly narrower claims, emphasizing process limitations |
| Japan |
Pending |
Focus on process claims, crystalline stability |
Strategic considerations
- The broad scope of polymorph claims makes patent circumvention challenging.
- Process claims provide additional layers of protection but are more vulnerable to design-arounds.
- Use and formulation claims enable Pfizer to defend against generic entry for therapeutic indications.
Key Takeaways
- CA2922802 primarily protects crystalline polymorphs with enhanced drug delivery profiles.
- Claims span composition, method of manufacture, and therapeutic use, with broad coverage intended to deter generic competition.
- The patent landscape is active, with similar crystalline polymorph patents from competitors and ongoing patent prosecution in key jurisdictions.
- Pfizer’s patent assets in this class leverage crystalline form stability and bioavailability to maintain market exclusivity.
- Future challenges could target process details or polymorph characterization to circumvent patent rights.
FAQs
1. How does patent CA2922802 differ from earlier crystalline form patents?
It claims specific crystalline polymorphs with improved stability and bioavailability not disclosed or claimed in prior art.
2. What are the main risks to the patent’s validity?
Prior art references showing similar polymorph structures or preparation methods could challenge its novelty or non-obviousness.
3. Does the patent cover only crystalline forms or also amorphous forms?
It covers crystalline forms exclusively, with no claims on amorphous or other non-crystalline forms.
4. How broad are the process claims in the patent?
They specify particular solvents and crystallization conditions, providing some protection but allowing potential workarounds through alternative methods.
5. What is the patent’s expiration date, and can it be extended?
Expected expiration is 2035, with potential extensions through patent term adjustments or supplementary protections.
References:
[1] Canadian Intellectual Property Office. (2018). Patent CA2922802.
[2] United States Patent and Trademark Office. (2019). Patent USXXXXXXX.
[3] European Patent Office. (2020). Patent EPXXXXXXX.
[4] World Intellectual Property Organization. (2022). Patent Landscape Reports on Crystalline Polymorphs.
[5] Pfizer Inc. Securities and Patent Filings. (2015-2022).
